Thierry Gil
A5103167970- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Cancer Treatment and Pharmacology
- Renal cell carcinoma treatment
- Sarcoma Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- Renal and related cancers
- Clinical practice guidelines implementation
- HER2/EGFR in Cancer Research
- Urinary and Genital Oncology Studies
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Cardiac tumors and thrombi
- Vascular Tumors and Angiosarcomas
- Lymphoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Pancreatic and Hepatic Oncology Research
- PARP inhibition in cancer therapy
- Urologic and reproductive health conditions
Institut Jules Bordet
2015-2024
Université Libre de Bruxelles
2013-2024
European Society for Medical Oncology
2018
Eurac Research
2018
RWTH Aachen University
2012
Merck (Germany)
2012
University Hospital Carl Gustav Carus
2012
Technical University of Munich
2012
Royal South Hants Hospital
2010
European Organisation for Research and Treatment of Cancer
1995-2010
We conducted a randomized, prospective trial comparing external irradiation with plus goserelin (an agonist analogue of gonadotropin-releasing hormone that reduces testosterone secretion) in patients locally advanced prostate cancer.From 1987 to 1995, 415 cancer were randomly assigned receive radiotherapy alone or immediate treatment goserelin. The had median age 71 years (range, 51 80). Patients both groups received 50 Gy radiation the pelvis over period five weeks and an additional 20 two...
Soft tissue sarcomas (STSs) gather over 80 histological entities, with even more molecular subsets, characterised by a low to very incidence in all populations. The majority of arise from the soft (close 75%), ∼15% gastrointestinal stromal tumours (GISTs) and 10% bone sarcomas. These ESMO–EURACAN (European Society for Medical Oncology–European Reference Network rare adult solid cancers) Clinical Practice Guidelines cover STSs, while GISTs are covered dedicated [1.Casali P.G. Abecassis N....
Purpose This is the first randomized phase II/III trial comparing two carboplatin-based chemotherapy regimens in patients with urothelial cancer who are ineligible (“unfit”) for cisplatin chemotherapy. Patients and Methods The primary objective of III part this study was to compare overall survival (OS) chemotherapy-naive measurable disease an impaired renal function (glomerular filtration rate < 60 but > 30 mL/min) and/or performance score 2 were randomly assigned receive either...
Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year [1.Nilsson B. Bümming P. Meis-Kindblom J.M. et al.Gastrointestinal tumors: the incidence, prevalence, clinical course, and prognostication in preimatinib mesylate era–a population-based study western Sweden.Cancer. 2005; 103: 821-829Crossref PubMed Scopus (1027) Google Scholar]. This only covers clinically relevant GISTs, since, if investigated, a much higher number...
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care cancer patients) database [1.Stiller C.A. Trama A. Serraino D. Descriptive epidemiology sarcomas Europe: report from RARECARE project.Eur J Cancer. 2013; 49: 684-695Abstract Full Text PDF PubMed Scopus (265) Google Scholar]. Different tumour subtypes have distinct patterns incidence, each has no more than 0.3 incident cases per 100...
BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor (VEGFR) inhibitor that targets tumour cell proliferation angiogenesis. This Phase I study was undertaken to determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics, response profile of oral in patients with advanced, refractory solid tumours. administered daily for repeated cycles 21 days on/7 off. A total 44 were enrolled at doses from 50 800 mg...
To assess the impact of a novel molecular imaging technique, 68 Ga-(HBED-CC)-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT), in clinical management patients with prostate cancer rising prostate-specific (PSA) after treatment curative intent.In all, 131 consecutive were referred to our centre for Ga-PSMA PET/CT setting recurring cancer. Of these patients, 11/131(8%) presented persistent PSA radical prostatectomy, while 120/131 (92%)...
<h3>Importance</h3> DCVAC/PCa is an active cellular immunotherapy designed to initiate immune response against prostate cancer. <h3>Objective</h3> To evaluate the efficacy and safety of plus chemotherapy followed by maintenance treatment in patients with metastatic castration-resistant cancer (mCRPC). <h3>Design, Setting, Participants</h3> The VIABLE double-blind, parallel-group, placebo-controlled, phase 3 randomized clinical trial enrolled mCRPC among 177 hospital clinics US Europe between...
Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does study add? It is now recognized that all patients with mRCC will eventually become resistant to VEGF inhibition. Although existing level 1 evidence supports use second‐line therapy, oral mTOR inhibitor Everolimus, recent data also indicates sequential inhibition an appropriate therapeutic manoeuver in this cohort patients. Targeting alternative signaling pathway Hepatocyte growth factor/c‐met...
<b>Aim:</b> We aimed to evaluate the role of Positron Emission Tomography (PET) targeting Prostate-Specific Membrane Antigen (PSMA) for response assessment in metastatic prostate cancer (mPCa) patients treated with taxane-based chemotherapy (docetaxel or cabazitaxel) and its predictive value on patient outcome. <b>Methods:</b> retrospectively evaluated 37 hormone-sensitive castration-resistant (mHSPC mCRPC) who underwent <sup>68</sup>Ga-PSMA-11 PET/CT at baseline after last cycle without...
Abstract Background MiT family translocation renal cell carcinoma (TRCC) is a rare and aggressive subgroup of harboring high expression c-MET. While TRCC response rates to VEGF receptor tyrosine kinase inhibitors (TKIs) immune checkpoint are limited, efficacy cabozantinib (a VEGFR, MET, AXL inhibitor) in this unclear. Methods We performed multicenter, retrospective, international cohort study patients with treated cabozantinib. The main objectives were estimate rate according RECIST 1.1...
20 Background: Metastatic castration-sensitive prostate cancer (mCSPC) primarily affects older men (OM). In this post-hoc analysis we investigated the safety and efficacy of abiraterone acetate + prednisone (AAP) in (≥ 70 years) younger (< patients PEACE-1. Methods: Men with de novo mCSPC were allocated to standard care (SOC), SOC AAP, radiotherapy (RXT), or AAP RXT 2x2 design phase 3 trial. was initially androgen deprivation therapy (ADT) alone, then from Oct 2015 onwards, use docetaxel...
The aim of the present study was to investigate efficacy paclitaxel following a first-line cisplatin regimen in patients with metastatic bladder cancer. retrospectively evaluated clinical effects and toxicities second-line regimens treatment A total 42 progressing urothelial cancer cisplatin-based chemotherapy were enrolled. received weekly (80 mg/m2) median duration 3 months. overall response rate, disease control rate progression free survival 9.5, 45.2 6.4 months, respectively. Weekly...
4517 Background: Nearly half of the patients (pts) diagnosed with non-metastatic muscle invasive bladder cancer are unfit for cisplatin therapy and no alternative options neoadjuvant treatment exist. Avelumab (A), a monoclonal antibody directed against PD-L1, showed efficacy in advanced urothelial cancer. We report preliminary data assessing preoperative avelumab associated paclitaxel gemcitabine or alone ineligible cohort. The results eligible cohort were reported at ESMO 2021. Methods:...